Pioneering microRNA solutions for the central nervous system
Spun out of Weizmann institute for Science in 2013, the company utilize RNA interference technology based on the robust scientific discoveries where a deep understanding of the biology behind microRNAs involvement in central nervous system (CNS) related disorders, was gained.
Treatment resistant depression therapy. A novel RNA interference proprietary targeting key mRNAs involved in depression.
miCure owns a technology of a non-invasive brain delivery of oligonucleotides like siRNAs, miRNAs and ASOs that allows targeting gene expression modulation in specific cell types (pathology related population). The technology is based on linking the oligonucleotide of interest to a ligand of a neurotransmitter transporter and was demonstrated to be effective in NHP studies.
miCure Therapeutics is a leading-edge biotech company established in September 2013 in the Science Park of Ness Ziona, Israel. The company is focused on micro-RNA
miCure Therapeutics is a leading-edge biotech company focused on micro-RNA therapeutics and diagnostics for the central nervous system. Current development program based on mir135 mimic